These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23722322)

  • 41. Drugs: An injection of hope.
    Graham-Rowe D
    Nature; 2012 Apr; 484(7393):S4. PubMed ID: 22509505
    [No Abstract]   [Full Text] [Related]  

  • 42. The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis.
    Fragoso YD; Arruda CC; Arruda WO; Brooks JB; Damasceno A; Damasceno CA; Finkelsztejn A; Finkelsztejn J; Gama PD; Giacomo MC; Gomes S; Goncalves MV; Matta AP; de Morais MM; Oliveira EM; Ribeiro Y; Sato HK; Tauil CB
    Arq Neuropsiquiatr; 2014 Sep; 72(9):712-4. PubMed ID: 25252236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Severe relapses under fingolimod treatment prescribed after natalizumab.
    Centonze D; Rossi S; Rinaldi F; Gallo P
    Neurology; 2012 Nov; 79(19):2004-5. PubMed ID: 23035063
    [No Abstract]   [Full Text] [Related]  

  • 44. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
    O'Connor P; Comi G; Montalban X; Antel J; Radue EW; de Vera A; Pohlmann H; Kappos L;
    Neurology; 2009 Jan; 72(1):73-9. PubMed ID: 19122034
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?
    Alroughani R; Almulla A; Lamdhade S; Thussu A
    BMJ Case Rep; 2014 Oct; 2014():. PubMed ID: 25320259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic interference with leukocyte recirculation in multiple sclerosis.
    Sellebjerg F; Sørensen PS
    Eur J Neurol; 2015 Mar; 22(3):434-42. PubMed ID: 25582213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fingolimod for multiple sclerosis.
    Pelletier D; Hafler DA
    N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823
    [No Abstract]   [Full Text] [Related]  

  • 48. Emerging disease-modifying oral therapies for multiple sclerosis.
    Losy J; Kalinowska-Łyszczarz A
    J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Azathioprine in multiple sclerosis.
    Invernizzi P; Benedetti MD; Poli S; Monaco S
    Mini Rev Med Chem; 2008 Aug; 8(9):919-26. PubMed ID: 18691149
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.
    Conzett KB; Kolm I; Jelcic I; Kamarachev J; Dummer R; Braun R; French LE; Linnebank M; Hofbauer GF
    Arch Dermatol; 2011 Aug; 147(8):991-2. PubMed ID: 21844470
    [No Abstract]   [Full Text] [Related]  

  • 51. Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient.
    Lysandropoulos AP; Benghiat F
    Mult Scler; 2013 Oct; 19(11):1551-2. PubMed ID: 23817558
    [No Abstract]   [Full Text] [Related]  

  • 52. [Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].
    Winkelmann A; Löbermann M; Reisinger EC; Zettl UK
    Nervenarzt; 2012 Feb; 83(2):236-42. PubMed ID: 21845450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cystoid macular edema associated with fingolimod use for multiple sclerosis.
    Afshar AR; Fernandes JK; Patel RD; Ksiazek SM; Sheth VS; Reder AT; Hariprasad SM
    JAMA Ophthalmol; 2013 Jan; 131(1):103-7. PubMed ID: 23307220
    [No Abstract]   [Full Text] [Related]  

  • 54. [Therapeutic effect of S1P receptor modifying drugs for autoimmune diseases].
    Chiba K; Kataoka H
    Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):24-5. PubMed ID: 18421849
    [No Abstract]   [Full Text] [Related]  

  • 55. [New therapies in multiple sclerosis].
    Roggerone S; Chenevier F; Confavreux C; Vukusic S
    Rev Prat; 2012 Oct; 62(8):1057-60. PubMed ID: 23227596
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
    Montalban X; Comi G; O'Connor P; Gold S; de Vera A; Eckert B; Kappos L
    Mult Scler; 2011 Nov; 17(11):1341-50. PubMed ID: 21727148
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.
    Heisen M; Treur MJ; van der Hel WS; Frequin ST; Groot MT; Verheggen BG
    J Med Econ; 2012; 15(6):1149-58. PubMed ID: 22737996
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Branch retinal vein occlusion during fingolimod treatment in a patient with multiple sclerosis.
    Gallego-Pinazo R; España-Gregori E; Casanova B; Pardo-López D; Díaz-Llopis M
    J Neuroophthalmol; 2011 Sep; 31(3):292-3. PubMed ID: 21826025
    [No Abstract]   [Full Text] [Related]  

  • 59. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumefactive multiple sclerosis lesions under fingolimod treatment.
    Visser F; Wattjes MP; Pouwels PJ; Linssen WH; van Oosten BW
    Neurology; 2012 Nov; 79(19):2000-3. PubMed ID: 23035065
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.